PE-22-28 vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | PE-22-28 | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Mechanism | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Very limited human data. Primarily studied in animal models for safety and efficacy. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |